Monte Rosa Therapeutics partners with Novartis in a $2B deal for autoimmune disease drug development.

Monte Rosa Therapeutics has partnered with Novartis in a deal potentially worth over $2 billion to develop molecular glue degraders, including MRT-6160, aimed at treating autoimmune diseases. Novartis will pay $150 million upfront and could provide additional milestone payments contingent on the drug's success. While Novartis will handle development from Phase 2 onward, Monte Rosa will continue its ongoing Phase 1 trial and share in U.S. profits and losses.

October 28, 2024
7 Articles